Last time was also a late breaking oral. Going after Biogen is interesting. “Confirms Role of Patient Biomarkers” is curious. How will they show it? They CANT just say. “See. The higher concentration patients were the ones that fit our profile and they were the ones that improved”
So, it has to be something new that CONFIRMS.
Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers
nidan, I don't like the 15 minutes either, but if it is the last presentation of the day, then CTAD might allow for an over-run of the 15 minutes.
There must be new disclosures in the Anavex presentation that has caught the eyes of CTAD people and they want to give it an opportunity to be unveiled.
News 
Market Data 
Discover 
